Group 1 - The core viewpoint of the news is that Huaxi Biological has reported a significant decline in its financial performance for the third quarter of 2025, with revenue and net profit both decreasing year-on-year [1] Group 2 - For the first three quarters of 2025, Huaxi Biological's revenue was approximately 3.163 billion yuan, representing a year-on-year decrease of 18.36% [1] - The net profit attributable to shareholders of the listed company was about 252 million yuan, down 30.29% year-on-year [1] - The basic earnings per share were 0.52 yuan, reflecting a decrease of 30.67% compared to the previous year [1] - As of the report date, Huaxi Biological's market capitalization stood at 25.4 billion yuan [2]

华熙生物科技股份有限公司 2025 年第三季度报告 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人赵燕女士、主管会计工作负责人汪卉先生及会计机构负责人（会计主管人员）田涛先 生保证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是√否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 比上年同 | 年初至报告期末 | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 902,707,051.31 | -15.16 | 3,163,398,568.64 | -18.36 | | 利润总额 | 31,208,800.95 | 62.91 | 291,533,228.00 | -33.22 | | 归属于上市公司股东的 净利润 | 31,5 ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-041 华熙生物科技股份有限公司 关于 2025 年第三季度计提大额资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 华熙生物科技股份有限公司（以下简称"公司"）根据财政部发布的企业会 计准则及其应用指南、解释及其他有关规定（统称："企业会计准则"）、公司 会计政策及会计估计的规定，基于谨慎性原则，对截至2025年9月30日合并报表 范围内可能发生信用及资产减值损失的有关资产计提了资产减值准备。 一、 计提资产减值准备的概述 2025 年第三季度，公司因计提应收账款坏账准备及其他应收款坏账准备而确 认信用减值损失 1,753.78 万元，因计提存货跌价准备而确认资产减值损失 571.30 万元，具体情况如下表所示： 单位：人民币万元 | 序号 | 项目 | 2025年上半年发 | 2025年第三季度 | 合计 | 备注 | | --- | --- | --- | --- | --- | --- | | | | 生金额 | 发生金额 | | | ...

Core Insights - Huaxi Biological announced a third-quarter revenue of 903 million yuan, a year-on-year decrease of 15.16% [1] - The net profit for the third quarter was 31.53 million yuan, a year-on-year increase of 55.63% [1] - For the first three quarters, the total revenue was 3.163 billion yuan, a year-on-year decrease of 18.36% [1] - The net profit for the first three quarters was 252 million yuan, a year-on-year decrease of 30.29% [1] Financial Performance - Third-quarter revenue: 903 million yuan, down 15.16% year-on-year [1] - Third-quarter net profit: 31.53 million yuan, up 55.63% year-on-year [1] - Year-to-date revenue (first three quarters): 3.163 billion yuan, down 18.36% year-on-year [1] - Year-to-date net profit (first three quarters): 252 million yuan, down 30.29% year-on-year [1]

Core Viewpoint - The medical beauty sector experienced a decline of 1.44% on October 28, with Jinbo Biological leading the drop. The Shanghai Composite Index closed at 3988.22, down 0.22%, while the Shenzhen Component Index closed at 13430.1, down 0.44% [1]. Group 1: Market Performance - The medical beauty sector's individual stock performance showed the following results: - Huaxi Biological closed at 52.72, down 1.03% with a trading volume of 18,000 shares and a transaction value of 95.6261 million yuan [1]. - *ST Meigu closed at 3.56, down 1.39% with a trading volume of 130,900 shares and a transaction value of 47.2460 million yuan [1]. - Aimeike closed at 163.54, down 1.74% with a trading volume of 32,100 shares and a transaction value of 529 million yuan [1]. - Jinbo Biological closed at 245.86, down 2.05% with a trading volume of 12,100 shares and a transaction value of 299 million yuan [1]. Group 2: Capital Flow - On the same day, the medical beauty sector saw a net outflow of 35.3969 million yuan from main funds, a net outflow of 24.4121 million yuan from speculative funds, and a net inflow of 59.809 million yuan from retail investors [2].

证券代码：688363 证券简称：华熙生物 公告编号：2025-040 华熙生物科技股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 10 月 27 日 （二） 股东会召开的地点：北京市朝阳区建国门外大街甲六号华熙国际中心 D 座 36 层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 221 | | --- | --- | | 普通股股东人数 | 221 | | 2、出席会议的股东所持有的表决权数量 | 298,195,892 | | 普通股股东所持有表决权数量 | 298,195,892 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 62.3368 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 62.3 ...

中国北京建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-14th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于华熙生物科技股份有限公司 2025 年第一次临时股东会的法律意见书 致：华熙生物科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）等法律、法规及规范性文件和《华熙生物科 技股份有限公司章程》（以下简称"《公司章程》"）的规定，北京市通商律 师事务所（以下简称"通商"或"本所"）接受华熙生物科技股份有限公司 （以下简称"公司"）委托，指派本所律师出席了公司于 2025 年 10 月 27 日召 开 ...

Core Insights - Huaxi Biological's core brand, Runbaiyan, has named two venues in Beijing and Chongqing as "Huaxi Biological・Runbaiyan ECM Center" [1] - The ECM Center integrates sports events, performing arts, and leisure commerce, becoming a cultural landmark and urban vitality center [1] - Huaxi Biological is one of the few companies globally that has a comprehensive layout in the ECM (extracellular matrix) field, focusing on the overall synergy of key ECM substances [1] Company Overview - Huaxi Biological is engaged in the research and development of key ECM substances, establishing a unified underlying technology and product planning for oral, external, and medical applications [1]

证券时报·数据宝统计，截至今日上午10:29，上证综指3981.95点，收于年线之上，涨跌幅为0.80%，A 股总成交额为12201.25亿元。到目前为止，今日有44只A股价格突破了年线，其中乖离率较大的个股有 威士顿、永福股份、智翔金泰等，乖离率分别为5.84%、5.49%、4.58%；七一二、哈尔斯、华熙生物等 个股乖离率较小，刚刚站上年线。 10月27日突破年线个股乖离率排名 | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 301315 | 威士顿 | 13.21 | 19.88 | 52.55 | 55.62 | 5.84 | | 300712 | 永福股 份 | 8.21 | 2.57 | 25.00 | 26.37 | 5.49 | | 688443 | 智翔金 泰 | 6.55 | 5.49 | 28.78 | 30.10 | 4.58 | | 002512 | 达华智 能 | 1 ...

Core Insights - The Chinese beauty industry has reached a milestone with Huaxi Biological's core brand, Runbaiyan, officially naming two landmark venues in Beijing and Chongqing as Huaxi Biological·Runbaiyan ECM Centers, marking the brand's significant exposure and strategic extension into urban markets [1][4] Group 1: Brand Strategy and Market Positioning - Runbaiyan's naming of the venues signifies its status as a domestic skincare brand that has successfully branded two major city landmarks [1] - The brand aims to transition from mere brand exposure to a scientific narrative, emphasizing the importance of ECM (extracellular matrix) in both biological and urban contexts [1][8] - The integration of cultural and sports events within these venues is expected to foster emotional connections and commercial prosperity, akin to how ECM supports cellular functions [8][11] Group 2: Scientific Foundation and Innovation - ECM is recognized as a fundamental component for life, influencing cellular organization and communication, and has been identified as a key factor in aging and tissue regeneration by international research [3][9] - Huaxi Biological has invested years in ECM research, aiming to translate scientific understanding into urban living experiences, thereby creating a connection between individuals and cities [3][9] - The scientific insights provided by experts highlight the role of hyaluronic acid in ECM, which is crucial for cellular signaling and regeneration, reinforcing the brand's commitment to scientific innovation [9] Group 3: Consumer Engagement and Experience - The newly established ECM Centers in Beijing and Chongqing will offer a unique blend of sports, entertainment, and leisure, creating vibrant cultural landmarks [11] - Runbaiyan plans to develop a multi-dimensional membership system that enhances consumer experiences by leveraging the foot traffic and cultural engagement at these venues [11][13] - Interactive elements, such as product sampling and exclusive event experiences, are designed to enrich consumer participation and connection with the brand [13][15]